{"filings":[{"id":2078596,"accession_number":"0001326732-26-000055","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2026-08-05T20:01:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor Q2 net loss $21.7M; Alexion settlement $105M; XmAb819 ESMO presentation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 revenue $51.2M (up from $43.6M YoY); net loss $21.7M ($0.29 loss per share) vs $30.8M loss in Q2 2025.","Alexion settlement resolves Ultomiris royalty dispute: $105M total, first $52.5M due Aug 2026, second $52.5M in 2027; no further U.S. royalties.","XmAb819 (ENPP3 x CD3) Phase 1 ccRCC data accepted for oral presentation at ESMO 2026; registration-enabling study planned for 2027.","XmAb541 (CLDN6 x CD3) monotherapy shows ~14% ORR in ovarian, ~28% in germ cell tumors; FDA Fast Track for germ cell; combination with XmAb808 prioritized.","Cash $486.4M at June 30, 2026; expects year-end 2026 cash $420-440M; sufficient to fund operations through 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1940565,"accession_number":"0001326732-26-000049","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2026-07-29T20:05:44+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Xencor settles Ultomiris U.S. royalty dispute with Alexion for $105M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Xencor to receive $105M in two equal payments: $52.5M in Aug 2026 and $52.5M in July 2027.","Alexion has no further obligation to pay U.S. royalties on Ultomiris; ex-U.S. royalties unchanged.","Cash runway extended through 2028 based on current operating plans.","Dispute began in March 2026 when Alexion claimed no further U.S. royalties were owed.","CEO Bassil Dahiyat says resolution provides immediate capital and reflects expected U.S. royalty value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1139796,"accession_number":"0001326732-26-000045","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2026-06-18T20:43:08+00:00","items":["5.07"],"status":"ready","headline":"Xencor stockholders elect nine directors, approve equity plan increase at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected; votes in favor ranged from 60.4M to 63.2M.","Ratification of KPMG as auditor for FY2026 approved with 63.8M votes for.","Amendment to 2023 Equity Incentive Plan adding 4M shares approved (52.0M for, 11.4M against).","Advisory vote on named executive officer compensation passed with 61.3M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92144,"accession_number":"0001326732-26-000042","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor reports Q1 net loss $128.9M ($1.71/shr); revenue down to $4.5M from $32.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 revenue $4.5M (vs $32.7M Q1 2025), including a $6.6M one-time reduction from Alexion royalty dispute.","Net loss $128.9M ($1.71 diluted), vs $48.4M ($0.66) in prior year; other expense $50.8M on unrealized equity losses.","Cash $541.8M at March end; guidance for year-end cash $380-400M, runway into mid-2028.","XmAb819 ccRCC expansion data to be presented 2H26; XmAb541 dose data also 2H26; XmAb412 FIH starts 3Q26.","XENITH-UC Phase 2b (XmAb942) blinded interim analysis around year-end 2026; primary endpoint 2H27."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":4516000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92143,"accession_number":"0001326732-26-000036","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xencor reports final Phase 1 data for XmAb942; predicts superior TL1A inhibition vs first-gen antibodies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["XmAb942 achieved 74.1-day half-life; supports single SC dose every 12 weeks during maintenance.","Modeling predicts >99% TL1A inhibition in 86% of patients during induction vs 31-40% for first-gen.","No serious TEAEs; ADA incidence 57% across doses but 0% neutralizing at high-dose tested in Phase 2b.","Global Phase 2b XENITH-UC enrollment on track; primary endpoint results expected H2 2027.","First-in-human study for XmAb412 (TL1A x IL23p19) on track to start in Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92142,"accession_number":"0001326732-26-000030","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xencor adopts Executive Severance Policy for VPs and above; severance up to 15 months base salary plus COBRA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Policy covers VPs (9 months), SVP (12 months), EVP (15 months) and C-level officers, excluding CEO.","Severance: lump sum base salary plus COBRA premiums for up to 15 months, contingent on release.","Change-in-control triggers additional bonus (target bonus for same months), prorated annual bonus, and full equity vesting acceleration.","Policy effective April 23, 2026; requires six months continuous employment and involuntary termination without Cause or Good Reason resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102757,"accession_number":"0001326732-26-000023","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Xencor receives Genentech/Roche termination notice for collaboration; effective Sept 4, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Genentech terminated Amended and Restated Collaboration & License Agreement for convenience, effective September 4, 2026.","Sole active product, efbalropendekin alfa, was removed from Roche's pipeline in January 2025.","Xencor ceased cost-sharing in H1 2024; Genentech assumed sole responsibility for development activities.","Termination had been anticipated after Roche's January 2025 pipeline announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102756,"accession_number":"0001326732-26-000021","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alexion refuses further US Ultomiris royalties; Xencor disputes, cuts revenue forecast","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Alexion informed Xencor it will not pay additional US royalties on Ultomiris and will cease future US payments.","Xencor previously expected $100-$120M in additional US royalties through 2028; now considers that revenue at risk.","Ex-US royalty payments from Alexion continue unchanged, per Xencor's CEO.","Xencor updates 2026 year-end cash guidance to $380-400M; operating runway extended into mid-2028.","Xencor is actively evaluating options and disagrees with Alexion's position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102755,"accession_number":"0001326732-26-000014","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor Q4 net loss narrows to $6.7M; XmAb819 dose expansion advances; Xtend royalty upside $100-120M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $28.2M (down 47% YoY), full year $125.6M (up 14%). Net loss $6.7M ($0.09/sh) vs $45.6M prior-year Q4.","Cash $610.8M at Dec 31, 2025; expects $400-430M at end 2026, funding operations through 2028.","XmAb819 (ENPP3 x CD3) dose expansion open in CRC, NSCLC, pRCC; plan to present data 2H26 for recommended Ph3 dose, pivotal start 2027.","Xtend U.S. patent to Dec 2028; expects $100-120M aggregate royalty above OMERS cap from Ultomiris sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":125576000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102754,"accession_number":"0001326732-26-000002","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor reports $611M cash; outlines 2026 pipeline milestones for XmAb candidates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Unaudited cash, equivalents & marketable debt securities ~$611M as of Dec 31, 2025 vs $706.7M a year ago.","Cash expected to fund operations through 2028 based on current plans.","XmAb819 (ENPP3xCD3) for ccRCC: 25% partial response; pivotal study planned in 2027.","XmAb541 (CLDN6xCD3) for gynecologic/germ cell tumors: confirmed partial responses in 3 of 9 patients; pivotal study planned in 2027.","Autoimmune pipeline: Phase 1b plamotamab in RA, Phase 1 XmAb657 in IIM, Phase 2b XENITH-UC, and first-in-human TL1AxIL23p19 in 2H26."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118990,"accession_number":"0001326732-25-000086","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor narrows Q3 net loss to $6M; advances key bispecific antibodies toward pivotal studies","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.0M ($0.08 per share) vs $46.3M loss ($0.72) in Q3 2024; revenue $21.0M, up from $17.8M.","Cash $633.9M at Sept 30, 2025; expects year-end cash $570-590M and runway into 2028.","XmAb819 (ccRCC) and XmAb541 (gynecologic/germ cell) show early PRs; Phase 3 dose selection in 2026; pivotal studies targeted for 2027.","First patient dosed in plamotamab Phase 1b RA study; XmAb942 Phase 2b XENITH-UC enrolling; XmAb657 and XmAb412 studies on track.","Partners advancing: Amgen Phase 3 XALience for xaluritamig; Astellas data on ASP2138; Zenas positive Phase 2 in MS."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":97339000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118989,"accession_number":"0001326732-25-000082","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xencor reports 25% ORR for XmAb819 in ccRCC Phase 1; dose-expansion cohort selected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["XmAb819 (ENPP3 x CD3) Phase 1: 25% ORR (5/20 PRs) and 70% DCR in target dose range in heavily pre-treated ccRCC.","All 5 responders remain on treatment; 50% (10/20) of evaluable patients in target range remain on treatment as of Sep 19, 2025.","Safety: CRS (Grade 3 in 4% with correct priming dose), no ICANS, no Grade 5 events; priming dose errors identified and remediated.","First dose-expansion cohort enrolled; expect Phase 3 dose selection in 2026, pivotal study start in 2027.","Early XmAb541 (CLDN6 x CD3) data also presented in ovarian, endometrial, and germ cell tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135532,"accession_number":"0001326732-25-000074","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor Q2 2025 revenue $43.6M, net loss $30.8M; Incyte milestone $25M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $43.6M (up from $23.9M Q2 2024); net loss $30.8M ($0.41/share) vs $67.3M ($1.09) prior year.","Cash and securities $663.8M (Dec 2024: $706.7M); guidance for year-end $555-585M, runway into 2028.","Earned $25M regulatory milestone from Incyte for Monjuvi FDA approval in follicular lymphoma.","Initiated Phase 2b XENITH-UC study of XmAb942 in ulcerative colitis; plans to present XmAb819 data in Q4 2025.","Appointed Raymond Deshaies, Ph.D., to board of directors; he previously led global research at Amgen."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":76340000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135531,"accession_number":"0001326732-25-000063","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xencor appoints Raymond Deshaies, Ph.D. to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Deshaies is a former SVP of global research at Amgen with 25+ years in biotech.","Received initial option grant with $550,000 Black-Scholes value; vests over 3 years.","Also receives $50,000 annual cash retainer; standard indemnification agreement.","Deshaies co-founded Proteolix (discovered carfilzomib/KYPROLIS) and Cleave Biosciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152524,"accession_number":"0001326732-25-000057","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xencor stockholders approve all four proposals at 2025 annual meeting; equity plan expanded by 3M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected, including Bassil Dahiyat and Todd Simpson, with >63M votes for each.","Ratification of KPMG as independent auditor for FY2025 passed with 66,996,453 votes for.","Equity incentive plan amendment approved, adding 3,000,000 authorized shares (49.3M for, 14.9M against).","Advisory vote on named executive officer compensation passed non-binding with 62.8M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152523,"accession_number":"0001326732-25-000052","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Xencor Q1 net loss narrows to $48.4M; CDO Valente resigns, Phase 2b UC study on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $32.7M (up from $16.0M YoY); net loss $48.4M (-$0.66 EPS) versus $73.4M (-$1.20 EPS) prior year.","Cash $693.5M at March 31; expects year-end 2025 cash $535-585M, funding operations into 2028.","Nancy Valente, EVP & CDO, to resign June 6, 2025, remain as senior advisor; clinical leaders report to CEO.","XmAb942 interim Phase 1 shows half-life >71 days, supports Q12W maintenance dosing; Phase 2b XENITH-UC starts H2 2025.","Earned $12.5M milestone from Incyte for tafasitamab sBLA acceptance, $2.0M from Vir for tobevibart Phase 3 start."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":32732000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152522,"accession_number":"0001326732-25-000048","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xencor reports positive interim Phase 1 results for XmAb942; half-life >71 days","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["XmAb942 well tolerated; no serious AEs, no discontinuations.","Half-life >71 days supports 12-week maintenance dosing in planned Phase 2b UC study.","Phase 2b XENITH-UC trial in moderate-to-severely active UC expected to start H2 2025 (n~220).","TL1A x IL23p19 bispecific lead selection on track; FIH study planned for 2026.","Company to host call at 5pm ET today."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171344,"accession_number":"0001326732-25-000035","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xencor appoints former Seagen CFO Todd Simpson to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Todd Simpson appointed to Xencor board on March 13, 2025, and named to Audit Committee.","Simpson received an initial stock option with Black-Scholes value of $550,000, vesting over 3 years.","He will receive $50,000 annual cash retainer as director and $10,000 for Audit Committee service.","Simpson served as CFO of Seagen for 18 years, leading finance, strategy, and international expansion.","Board appointment expands Xencor's financial and corporate strategy expertise with a seasoned biopharma CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171339,"accession_number":"0001326732-25-000037","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K/A","filed_at":"2025-03-13T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Xencor dismisses auditor RSM, appoints KPMG after material weaknesses and restatement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed RSM on Feb 27, 2025; engaged KPMG effective March 3, 2025.","Material weaknesses in internal controls over royalty sale accounting and tax legislation led to restatement of 2023 annual and Q1-Q3 2024 interim financials.","RSM recalled its 2023 audit reports on internal controls and financial statements.","Additional material weakness in impairment analysis of Zenas equity investment existed Q1-Q2 2024, remediated by Q3 2024.","Company has implemented remediation plans for the material weaknesses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171343,"accession_number":"0001326732-25-000032","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Xencor dismisses RSM as auditor over material weaknesses; appoints KPMG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RSM dismissed Feb 27, 2025; KPMG appointed effective Mar 3, 2025.","Material weaknesses in controls over non-routine royalty sale accounting and tax legislation led to restatement of FY2023 and Q1-Q3 2024 financials.","RSM recalled its 2023 audit opinions and interim reviews; internal control reports flagged weaknesses.","Additional material weakness in impairment analysis of Zenas equity investment was remediated by Q3 2024.","No disagreements with RSM; company requested letter to SEC, not yet received."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171342,"accession_number":"0001326732-25-000028","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor Q4 net loss widens to $45.6M; full-year revenue falls 37% to $110.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $52.8M (+3.5% YoY) driven by milestone payments; full-year revenue $110.5M vs $174.6M.","FY 2024 net loss $232.6M ($3.58 diluted EPS) vs $133.1M ($2.20); R&D spend dropped to $227.7M.","Cash $706.7M at Dec 31; 2025 guidance $535-585M, runway into 2028.","Pipeline: XmAb942 healthy-volunteer data 1H 2025; XmAb819 ccRCC data 2H 2025; plamotamab RA Ph1b/2a start 1H 2025.","Vudalimab development paused; milestone revenue of $30M (Amgen) and $4M (Novartis) received in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":110493000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171341,"accession_number":"0001326732-25-000005","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["4.02","9.01"],"status":"ready","headline":"Xencor restates FY2023 and Q1-Q3 2024 results; errors in royalty accounting and tax","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty transaction with OMERS Life Sciences misclassified as deferred income instead of debt; impacted balance sheet by ~$168.5M debt understatement.","Estimated FY2023 impact: revenue understated by $6.3M, interest expense understated by $5.5M; operating cash flow overstated by $163M.","Additional tax errors: R&D expense under Section 174 and state tax lead to ~$7.8M shareholder equity overstatement for FY2023.","Material weaknesses identified in internal control over financial reporting related to both royalty and tax errors.","RSM US LLP recalls its audit reports on 2023 financials and internal controls; company will file amendments before 2024 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171340,"accession_number":"0001326732-25-000002","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xencor: $707M cash; XmAb541 selectivity; plamotamab B-cell depletion; XmAb808 dose escalation; vudalimab enrollment done","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash & marketable securities ~$707M at Dec 31, 2024, up from $697M in 2023; expected to fund ops into 2028.","New preclinical data shows XmAb541 (CLDN6 x CD3) selective binding to CLDN6 over CLDN9.","Plamotamab (CD20 x CD3) Phase 1 data shows deep peripheral B-cell depletion in lymphoma patients.","XmAb808 (B7-H3 x CD28) has resumed dose escalation in clinical study.","Enrollment completed in three ongoing vudalimab (PD-1 x CTLA-4) studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188331,"accession_number":"0001326732-24-000059","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor Q3 net loss $45.1M ($0.71 EPS), revenue down 82% YoY; cash $754M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $45.1M ($0.71 diluted EPS) vs net loss of $24.3M ($0.40) in Q3 2023.","Revenue of $10.7M, down 82% YoY from $59.2M, driven by lower milestone and royalty revenue.","Cash and marketable securities $754.3M as of Sept 30, 2024, up from $697M at Dec 31, 2023; includes $189.2M net proceeds from September public offering.","Program updates: XmAb942 Phase 1 started; plamotamab Phase 1b/2a in RA planned H1 2025; XmAb808 DLTs in highest dose cohort.","Amgen's xaluritamig advancing to Phase 3 in mCRPC; Xencor expects 2024 year-end cash $690-710M, funding into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":40475000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188330,"accession_number":"0001326732-24-000052","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xencor director Dagmar Rosa-Bjorkeson will not seek reelection at 2025 Annual Meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dagmar Rosa-Bjorkeson informed board on Sept 30, 2024 of her intent not to stand for reelection.","Reason cited is pursuit of another business opportunity; no disagreement with Xencor's operations or policies.","Board will continue recruiting additional members with complementary skillsets.","Ms. Rosa-Bjorkeson served as director since 2019 and was on audit and nominating/governance committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204807,"accession_number":"0001326732-24-000048","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xencor closes public offering of 8.1M shares at $18, raising ~$201M in gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering included 8,093,712 shares at $18.00/share and pre-funded warrants for 3,088,888 shares at $17.99/warrant.","Gross proceeds of ~$201.3M; net proceeds for R&D, capex, working capital, and general corporate purposes.","Underwriters exercised in full their option to purchase 1,458,600 additional shares.","Leerink Partners, Raymond James, and RBC Capital Markets acted as joint book-running managers; Wedbush PacGrow as co-manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204806,"accession_number":"0001213900-24-077934","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Xencor prices $175M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 6,635,112 shares at $18.00/share and pre-funded warrants for 3,088,888 shares at $17.99 each.","Gross proceeds ~$175M before underwriting discounts; expected close Sept 12, 2024.","Net proceeds for general corporate purposes including R&D, capex, working capital, and G&A.","Underwriters granted 30-day option for up to 1,458,600 additional shares; directors/officers locked up until Nov 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204805,"accession_number":"0001326732-24-000046","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Xencor unveils autoimmune pipeline, reports initial XmAb819 RECIST responses in ccRCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["XmAb942 (anti-TL1A) Phase 1 healthy volunteer study starts Q4 2024; interim data in H1 2025.","Plamotamab (CD20xCD3) Phase 1b/2a in multi-drug resistant RA to begin H1 2025.","XmAb657 (CD19xCD3) Phase 1 in autoimmune disease starts H2 2025; preclinical B-cell depletion >99.98%.","XmAb819 (ENPP3xCD3) shows RECIST responses in ccRCC; dose escalation continues, target dose by YE 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204804,"accession_number":"0001326732-24-000041","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor Q2 net loss widens to $66M; revenue falls 63% YoY to $17M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $66.0M ($1.07 diluted EPS) vs $22.0M ($0.37) in Q2 2023; net loss $134M YTD.","Revenue $17.0M, down from $45.5M; primarily non-cash royalty and licensing; no J&J milestone.","Cash $585M as of June 30, down from $697M at Dec 31; FY2024 cash guidance $475-525M.","Regained exclusive worldwide rights to plamotamab (CD20 x CD3), a Phase 2-ready bispecific T-cell engager.","Vudalimab (PD-1 x CTLA-4) data update and advancement decision for mCRPC expected H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":29765000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221660,"accession_number":"0001326732-24-000036","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xencor stockholders elect all eight directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected with >49M votes for; highest vote-getter Dr. Dahiyat with 52.9M for.","RSM US LLP ratified as independent auditor for FY2024: 55.7M for, 1.0M against.","Advisory vote on named executive officer compensation approved: 51.6M for, 2.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221659,"accession_number":"0001326732-24-000034","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xencor Regains Exclusive Worldwide Rights to Plamotamab After Janssen Termination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Xencor regains worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen terminates its rights.","Plamotamab is Phase 2 ready, having completed Phase 1 enrollment in hematologic cancers in late 2023.","Janssen retains rights to develop B-cell targeting CD28 bispecifics, including JNJ-9401 and JNJ-1493, now in Phase 1.","Two collaboration agreements with Janssen continue; Xencor remains eligible for milestones and royalties on retained CD28 programs.","Xencor has opt-in rights to co-fund development of JNJ-9401 (20%) and JNJ-1493 (15%) upon proof-of-concept."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221658,"accession_number":"0001326732-24-000030","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor Q1 2024 net loss $68.0M ($1.11/share); revenue down to $12.8M from $19.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $68.0M from $60.8M YoY; diluted EPS -$1.11 vs -$1.02.","Revenue fell to $12.8M from $19.0M; non-cash royalty revenue vs prior milestone revenue.","Cash and marketable securities $646.7M at March 31, down from $697.4M at year-end 2023.","First patient dosed in Phase 1 for XmAb541 (CLDN6 x CD3) in solid tumors.","Appointed Bart Cornelissen as new CFO; expects cash runway into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":12805000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221657,"accession_number":"0001326732-24-000012","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xencor appoints Bart Cornelissen as CFO; John Kuch retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Kuch retired as CFO effective March 31, 2024; stepped down April 9, 2024; remains in non-executive role.","Bart Cornelissen appointed SVP and CFO April 9, 2024; previously VP corporate finance at Seagen (facilitated $43B Pfizer acquisition).","Compensation: $465K base, 45% bonus target, option grant of 190,194 shares ($2.25M), RSU grant ~$1M.","Severance includes 12 months base salary plus COBRA; full equity vesting upon change-in-control after one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241202,"accession_number":"0001326732-24-000009","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xencor posts Phase 2 data for vudalimab (PD1 x CTLA-4) in mCRPC","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Additional clinical data from Phase 2 study of vudalimab monotherapy in metastatic castration-resistant prostate cancer posted on website.","Presentation includes vudalimab, a bispecific PD1 x CTLA-4 antibody, corporate overview.","No specific efficacy/safety figures provided in the filing; refer to full presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241201,"accession_number":"0001326732-24-000002","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor Q4 2023 net loss $19.1M ($0.31 EPS); cash $697.4M; workforce cut ~10%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $44.7M vs $21.6M YoY; full-year net loss $126.1M ($2.08) vs $55.2M ($0.93) in 2022.","Cash and marketable securities $697.4M at Dec 31, 2023; guidance for end-2024 $475M-$525M, runway into 2027.","Vudalimab in high-risk mCRPC showed 33% ORR (4/12) and PSA90 in 25%; plans to advance or decide by H1 2025.","J&J milestones: $27.5M in Q4 2023; two new CD28 candidates selected; workforce cut ~10% in Jan 2024.","Pausing cytokine programs XmAb564 (IL2-Fc) and XmAb662 (IL12-Fc) after data review; dosing first patient for XmAb541 in H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":168338000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258671,"accession_number":"0001326732-23-000044","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Xencor converts Genentech collaboration to royalty/milestone deal; up to $600M in milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New agreement replaces cost/profit-sharing with tiered royalties (low double-digit to mid-teens percent) starting June 1, 2024.","Xencor eligible for up to $600M in milestones: $115M development, $185M regulatory, $300M sales-based.","Genentech assumes sole responsibility for all clinical, regulatory, and commercial activities post-effective date.","Original collaboration agreement remains in effect until May 31, 2024; Xencor had exercised royalty conversion option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258670,"accession_number":"0001326732-23-000039","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor receives $215M royalty payment, Q3 net loss $(0.40)/share; cash runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Royalty transaction with OMERS yields $215M upfront for portions of Ultomiris and Monjuvi royalties; cash runway extended to 2027.","Q3 revenue $59.2M, net loss $24.3M ($0.40 EPS) vs net loss $32.8M ($0.55 EPS) in Q3 2022.","Discontinued XmAb104 (PD-1 x ICOS) after Phase 1 expansion missed efficacy criteria; narrowed vudalimab enrollment.","Converted Genentech IL-15 co-development to milestone/royalty; plans to file IND for CLDN6 x CD3 (XmAb541) by year-end.","CFO John Kuch to retire March 2024; search for replacement initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":123649000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258669,"accession_number":"0001326732-23-000038","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Xencor sells Ultomiris and Monjuvi royalty rights to OMERS for $215M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OMERS pays $192.5M for Ultomiris royalties from July 2023 through end-2025, then annual caps starting in 2026.","OMERS pays $22.5M for Monjuvi royalties until OMERS receives 1.3x purchase price; excess reverts to Xencor.","Xencor eligible for an additional $12M milestone from OMERS if certain Ultomiris sales targets met.","Xencor retains economic upside above annual royalty caps ($35M from 2026-2028, $12M from 2029 onward).","Cash proceeds strengthen balance sheet to fund internal pipeline programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258668,"accession_number":"0001326732-23-000030","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xencor CFO John Kuch to retire in March 2024 after 23 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Kuch, SVP and CFO, notified Xencor of retirement effective March 31, 2024.","He will support the search for a new CFO and enter a consulting agreement post-transition.","Kuch joined Xencor in 2000 as finance director and played key role in IPO and financings.","CEO Bassil Dahiyat thanked Kuch for over two decades of leadership and critical contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275980,"accession_number":"0001326732-23-000028","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2023-09-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xencor adds Barbara Klencke, M.D., to board; board expands to eight members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 7 to 8 members; Dr. Klencke appointed effective Sept 15, 2023.","Dr. Klencke receives initial stock option with Black-Scholes value of $550,000, vesting over 3 years.","Annual cash retainer of $50,000 for board service; standard indemnification agreement.","Dr. Klencke previously CMO and CDO at Sierra Oncology; led Ojjaara approval for myelofibrosis.","Also serves on boards of eFFECTOR Therapeutics, Immune-Onc Therapeutics, and TScan Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275979,"accession_number":"0001326732-23-000024","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor Q2 2023 revenue $45.5M up 51% YoY; net loss narrows to $22M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $45.5M (vs $30.2M Q2 2022), net loss $22.0M ($0.37/diluted) vs $34.0M loss ($0.57) prior.","Cash, equivalents and marketable securities $531.4M at June 30, 2023, down from $613.5M at Dec 31, 2022.","Royalty revenue from Alexion's Ultomiris $11.2M; $10M milestone from Zenas for obexelimab Phase 3 start.","R&D expenses $60.1M, up 28% YoY; guidance projects year-end cash $425-475M, funding through 2025.","Vudalimab Phase 2 front-line NSCLC expected by year-end; XmAb662 Phase 1 started; XmAb541 IND planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":64485000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275978,"accession_number":"0001326732-23-000019","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xencor enters separation agreement with departing EVP Allen Yang; $520K severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Allen Yang's employment terminated June 30, 2023; he stepped down as executive officer effective May 1, 2023.","Separation agreement provides $520,000 severance (12 months base salary), $117,000 prorated bonus, and health coverage for 12 months.","No other changes to executive team; filing under Item 5.02 for compensatory plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293607,"accession_number":"0001326732-23-000007","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xencor stockholders elect all seven directors and approve 2023 Equity Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven directors elected; one director (Dagmar Rosa-Bjorkeson) received 11.3M withhold votes, still elected.","Ratification of RSM US LLP as auditor for FY2023 passed with 57.8M votes for vs 0.58M against.","Say-on-pay passed with 53.9M for, 1.8M against; advisory frequency set to one year.","2023 Equity Incentive Plan approved with 45.7M for, 10.0M against; turn-out 96.63% of outstanding shares.","Over 58.4M shares voted; broker non-votes affected proposals requiring non-routine items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293606,"accession_number":"0001628280-23-016465","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor Q1 net loss of $60.8M vs prior-year net income; revenue down to $19.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $60.8M ($1.02 diluted EPS) vs net income of $23.6M ($0.39 EPS) in Q1 2022.","Revenue fell to $19.0M from $85.5M YoY; included $10.5M Alexion royalties and Janssen milestone.","Cash, equivalents, receivables and marketable securities at $568.2M as of March 31, 2023.","Full-year 2023 cash guidance at $425-475M; expects funding through end of 2025.","Appointed Nancy Valente as EVP, Chief Development Officer effective May 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":18962000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293605,"accession_number":"0001628280-23-013066","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Xencor appoints Nancy Valente as EVP, Chief Development Officer; board reduced to 7","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nancy Valente appointed EVP and Chief Development Officer effective May 1, 2023; she resigned from board.","Valente previously SVP at Genentech/Roche; led development of GAZYVA, VENCLEXTA, POLIVY, HEMLIBRA.","Compensation: $540K base salary, 50% bonus target, option grant for 235,778 shares ($3.9M), RSU grant of 39,269 shares ($1.3M).","Allen Yang steps down as executive officer effective May 1 but stays in non-executive role.","Board size reduced from 8 to 7 to eliminate vacant seat left by Valente."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314236,"accession_number":"0001628280-23-007608","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Xencor confirms no deposits or securities at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Xencor reports it does not hold any deposits at Silicon Valley Bank.","Xencor states it does not hold any securities at Silicon Valley Bank.","Xencor confirms it does not maintain any accounts at Silicon Valley Bank."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314235,"accession_number":"0001628280-23-005593","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Xencor enters into $200M ATM equity offering program with SVB Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $200M of common stock may be sold at the market through SVB Securities under Sales Agreement dated Feb 27, 2023.","Sales agent compensation capped at 3.0% of gross proceeds; net proceeds for R&D, capex, working capital.","Company not obligated to sell any shares; program can be suspended or terminated by either party at any time.","No current acquisition plans, though proceeds could be used for investments in complementary businesses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314234,"accession_number":"0001628280-23-004846","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xencor Q4 2022 net loss $12M vs net income $73.1M; revenue $21.6M down 86% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $(0.20) vs EPS $1.21 in Q4 2021; full year net loss $55.2M.","Total revenue $21.6M in Q4 2022 vs $154.0M in Q4 2021; full year revenue $164.6M vs $275.1M.","Cash and securities $613.5M as of Dec 31, 2022; expects to end 2023 with $425-475M.","R&D expenses $51.5M in Q4, comparable to prior year; full year R&D $199.6M up from $192.5M.","Initiated Phase 1 for XmAb819 (ENPP3xCD3) and XmAb808 (B7-H3xCD28); IND for XmAb541 planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":164579000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332663,"accession_number":"0001558370-22-016645","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xencor Q3 net loss $32.8M ($0.55/sh); XmAb564 shows durable Treg expansion in Phase 1a","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $27.3M (up from $19.7M); net loss $32.8M vs $40.2M loss year ago.","Cash $654.6M; funding through 2025; year-end 2022 cash guided at $575-600M.","XmAb564 Phase 1a: single-dose well-tolerated; 117-fold peak CD25 bright Treg expansion; Phase 1b in atopic dermatitis/psoriasis started.","Vudalimab Phase 2 in mCRPC; plamotamab Phase 2 enrolling; data at SITC and ASH.","Vir royalty $17.8M in Q3; Zenas raised $118M, plans Phase 3 for obexelimab."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":142969000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350125,"accession_number":"0001558370-22-014299","cik":1326732,"company_name":"Xencor Inc","ticker":"XNCR","form_type":"8-K","filed_at":"2022-09-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xencor appoints Nancy Valente to board; Yujiro Hata resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nancy Valente, M.D., appointed to Board on Sept 8, 2022; she brings 20+ yrs pharma experience.","Yujiro Hata's resignation accepted by Board on Sept 8, 2022; he served since 2015.","Valente receives initial option grant valued at $550k (Black-Scholes) plus $50k annual cash retainer.","Valente most recently SVP at Genentech/Roche, led global oncology/hematology product development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":771810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-09-09T23:59:59+00:00|350125"}